Bavarian initiates new arm of phase III Covid-19 vaccine trial
The first patient has already been dosed in the US, and the Danish vaccine maker is now expanding the study to include Denmark and Belgium.
by marketwire, translated by daniel pedersen
Bavarian Nordic is about to begin the second arm of a phase III study of its Covid-19 vaccine candidate, ABNCoV2, in Denmark and Belgium, the company reports in a press release according to Danish business daily Børsen.
In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.
The US retail chain has stopped selling its own private label hearing aids – and until the next generation comes along, other hearing companies selling products via Costco are enjoying the empty shelf space.